Allergy Therapeutics presents progress at AAAAI

Allergy Therapeutics presents further scientific progress in its pollen and food-allergy research portfolio at the 2026 AAAAI Annual Meeting

26 February 2026 - Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, today announces that it will be sharing key scientific findings from across its research portfolio at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, taking place in Philadelphia, Pennsylvania from tomorrow, 27 February to 2 March 2026.

The 2026 AAAAI Annual Meeting is a premier conference in the field of allergy, asthma and immunology, hosted by the American Academy of Allergy, Asthma & Immunology (AAAAI), a leading membership organisation of more than 7,000 allergists/immunologists and related professionals around the world.

Among its three posters being presented, Allergy Therapeutics will share:

• Positive biomarker and clinical data demonstrating that Grass MATA MPL effectively induces tolerogenic properties through modulation of both humoral and cellular immune responses, with a statistically significant improvement of −22.5% in Combined Symptom Medication Score (P<0.00004) compared to placebo across the G306 and G309 Phase III clinical trials, supporting the Group's short-course subcutaneous allergen-specific immunotherapy (SCIT) as an effective and well-tolerated treatment for seasonal allergic rhinitis
• Supportive short-term blinded safety data from the first cohort of 190 paediatric participants in the G308 Phase III long-term adaptive trial investigating Grass MATA MPL in children and adolescents with grass pollen-induced seasonal allergic rhinitis, demonstrating a benign safety profile and a low trial discontinuation rate
• Positive safety, tolerability and interim biomarker data from the Phase I/IIa PROTECT clinical trial of VLP Peanut, the Group's innovative, short-course peanut allergy immunotherapy candidate, in healthy and peanut-allergic adults, confirming its potential as a promising therapeutic candidate for peanut allergy treatment

Manuel Llobet, Chief Executive Officer at Allergy Therapeutics, said: "The three presentations at this year's AAAAI Annual Meeting reflect the breadth and momentum of our clinical portfolio. The combined biomarker and efficacy data across two Phase III trials reinforce the compelling profile of Grass MATA MPL as a differentiated short-course immunotherapy, while the supportive paediatric safety data from G308 further extend the evidence base into a younger patient population. In parallel, the continued progress of our VLP Peanut programme demonstrates the versatility of our platform approach. Following the recent regulatory approval of Grass MATA MPL in Germany, the first subcutaneous grass pollen immunotherapy to be authorised under the TAV framework, these data mark another important step in our mission to deliver innovative, disease-modifying therapies for allergy sufferers worldwide."

The complete list of Allergy Therapeutics-sponsored abstracts accepted by AAAAI for presentation are available on the Group's website.

No new material price sensitive information will be disclosed on Allergy Therapeutics at the 2026 AAAAI Annual Meeting.